Sem A G Engels
Overview
Explore the profile of Sem A G Engels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin M, Aguilar-Rosas S, Franke K, Pieterse M, van Langelaar J, Schreurs R, et al.
Cancer Immunol Res
. 2024 Apr;
12(6):759-778.
PMID: 38573707
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame...
2.
Hofman D, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser K, et al.
Mol Cell
. 2024 Jan;
84(2):261-276.e18.
PMID: 38176414
A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively oncogenic non-canonical open reading frames (ORFs). To...
3.
Hofman D, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser K, et al.
bioRxiv
. 2023 May;
PMID: 37205492
A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively oncogenic non-canonical open reading frames. To address...
4.
Banducci-Karp A, Xie J, Engels S, Sarantaris C, van Hage P, Varela M, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980169
Damage-Regulated Autophagy Modulator 1 (DRAM1) is an infection-inducible membrane protein, whose function in the immune response is incompletely understood. Based on previous results in a zebrafish infection model, we have...
5.
Cornel A, Dunnebach E, Hofman D, Das S, Sengupta S, van den Ham F, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36521927
Background: Immunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed...
6.
Palomar-Siles M, Heldin A, Zhang M, Strandgren C, Yurevych V, van Dinter J, et al.
Cell Death Dis
. 2022 Nov;
13(11):997.
PMID: 36433934
TP53 nonsense mutations in cancer produce truncated inactive p53 protein. We show that 5-FU metabolite 5-Fluorouridine (FUr) induces full-length p53 in human tumor cells carrying R213X nonsense mutant TP53. Ribosome...